Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02579928 · ClinicalTrials.gov registry record · Phase 4
Ketamine Infusion for Adolescent Depression and Anxiety
A Phase 4 study of Major Depressive Disorder and Anxiety Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT02579928 is a Phase 4 study of Major Depressive Disorder and Anxiety Disorder that has completed, run by Yale University. The registered enrollment target is 17 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02579928, a Phase 4 study of Major Depressive Disorder and Anxiety Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the tolerability and short-term efficacy of a single ketamine infusion for the treatment of adolescents with 1) medication-refractory major depressive disorder (MDD) and/or 2) medication-refractory anxiety disorders (social anxiety disorder, panic disorder, generalized anxiety disorder and/or separation anxiety disorder).
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Midazolam
Study Locations (2)
Connecticut
- Hospital Research Unit at the Yale New Haven Hospital - New Haven
- Yale Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02579928
The ClinicalTrials.gov registry entry for NCT02579928 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT02579928 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02579928 about?
NCT02579928 is a clinical study titled "Ketamine Infusion for Adolescent Depression and Anxiety". The purpose of this study is to determine the tolerability and short-term efficacy of a single ketamine infusion for the treatment of adolescents with 1) medication-refractory major depressive disorder (MDD) and/or 2) medication-refractory anxiety disorders (social anxiety disorder, panic disorder, ...
What is the current status of trial NCT02579928?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2015-10. Estimated completion is 2019-09.
What conditions does trial NCT02579928 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Anxiety Disorder.
What interventions are being tested in trial NCT02579928?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT02579928?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02579928 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.